By Christina Loguidice

Articles

Personalized Medicine Is Gaining Momentum in Advanced Endometrial Cancer

July 9th 2021

Molecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.

FDA Approves Expanded Use of Tykerb

May 18th 2010

On January 29, the FDA expanded indications for lapatinib (Tykerb) to include its use in combination with the aromatase inhibitor letrozole (Femara) to treat hormone-positive and HER2-positive advanced breast cancer in postmenopausal women.

Combination Regimen Prolongs PFS in Recurrent Ovarian Cancer but Decreases Quality of Life

May 17th 2010

According to a study presented at the Society of Gynecologic Oncology 41st Annual Meeting on Women's Cancer, held in San Francisco, California, a combination of docetaxel(Taxotere) and carboplatin almost doubled progression-free survival (PFS) in patients with recurrent, platinum-sensitive ovarian cancer.

Study Sheds Light on How Palonosetron Prevents Delayed CINV

May 13th 2010

Palonosetron (Aloxi) is the only 5-HT3 receptor antagonist approved for treatment of delayed chemotherapy-induced nausea and vomiting (CINV) following administration of moderately emetogenic chemotherapeutic agents.

x